← Spyre Therapeutics, Inc. (SYRE) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Spyre Therapeutics, Inc. (SYRE)
Pharmaceutical Preparations · market cap $7.8B · as of 2026-07-12
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-31 (est.)
Phase 2
Pipeline
2
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Spyre Therapeutics (SYRE) is a clinical-stage pharmaceutical company with a market cap of ~$8.5B and 95 employees, developing SPY002-072 (Phase 2, Rheumatoid Arthritis) and SPY001 (Phase 2, Ulcerative Colitis). The stock trades at ~$97.74 with only ~$97.2M cash on hand, implying a runway of roughly 5 months, creating acute near-term financing pressure ahead of key data readouts expected in Q3-Q4 2026.
The catalyst path
- 2026-10-31 (est.)Phase 2 · SPY002-072imp 7/10
- 2026-11-03 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| SPY002-072 | Phase 2 | Rheumatoid Arthritis |
| SPY001 | Phase 2 | Ulcerative Colitis |
Price & technical context
3-month
+5.0%
6-month
+95.9%
12-month
+466.2%
52-wk range
$15.89–$108.92
vs 50-day MA
-2.9%
vs 200-day MA
+37.8%
Realized vol
67.0%
Max drawdown
-70.2%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for SYRE (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.